Combined IL-22 Inhibition With Existing Therapies for MDS Anemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myelodysplastic syndromes (MDS) and anemia associated with MDS, particularly in patients with del(5q) MDS, are inadequate, with no new FDA-approved drugs in the past decade, and existing therapies provide limited survival benefits and do not address the underlying molecular mechanisms of anemia.
Innovation Solution
Targeting IL-22 signaling pathways by administering down-regulators such as anti-IL-22 antibodies or agents that inhibit IL-22 activity, combined with existing therapies like lenalidomide, azacitidine, or erythropoiesis-stimulating agents, to promote erythroid progenitor cell differentiation and treat anemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies (lenalidomide, azacitidine) are used to treat MDS, then anemia is partially managed, but survival benefit is limited and resistance develops
Solution Approach 1:
The patent combines IL-22 signaling pathway inhibition with existing MDS therapies (lenalidomide, azacitidine, erythropoiesis-stimulating agents) to create a multi-target treatment approach. This combination therapy addresses both the immune activation component (via IL-22 inhibition) and the underlying MDS pathology (via existing agents), thereby extending survival benefit beyond what single-agent therapies can achieve while maintaining anemia management effectiveness.
Solution Approach 2:
The patent introduces IL-22 inhibitors as an intermediary agent that blocks the harmful IL-22 signaling pathway, which mediates immune activation and erythroid progenitor suppression in MDS. By targeting this intermediate pathway, the therapy amplifies the effectiveness of existing treatments and overcomes resistance mechanisms without directly replacing them.
2Ease of operation
If single-agent therapies are used, then treatment simplicity is maintained, but resistance to therapy develops
Solution Approach 1:
The patent merges IL-22 pathway inhibition with standard MDS therapies into a coordinated treatment regimen. This combination approach maintains relative treatment simplicity by building upon familiar therapeutic frameworks while adding the IL-22 inhibitory component, thereby preventing resistance development without significantly complicating the treatment protocol.
Solution Approach 2:
The patent employs IL-22 inhibition as a preliminary action that prevents the development of resistance to existing MDS therapies. By blocking the IL-22 signaling pathway upfront, the treatment prevents the immune activation and adaptive resistance mechanisms that would otherwise develop during monotherapy, thereby maintaining long-term therapy effectiveness.
3Productivity
If IL-22 signaling is down-regulated, then erythroid progenitor differentiation is promoted, but immune activation is reduced
Solution Approach 1:
The patent converts the harmful effect of IL-22-driven immune activation into a beneficial therapeutic mechanism. By inhibiting IL-22 signaling, the treatment eliminates the harmful immune activation that suppresses erythroid progenitors, while simultaneously promoting red blood cell differentiation. The same pathway inhibition that reduces immune activation directly benefits erythropoiesis.
Data Source
AI summary
The present invention relates, in part, to methods for treating red blood cell disorders, such as an MDS and/or an anemia, by down-regulating IL-22 signaling.